Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-CD40/TNFRSF5 Antibody (R3G90)

Catalog #:   RHD68904 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM
Accession: P25942
Overview

Catalog No.

RHD68904

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400

Target

Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P25942

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3G90

Data Image
  • Flow Cytometry
    Flow cytometric analysis of Hela cells using CD40 mouse mAb (green) and negative control (red).
References

Mechanistic investigation of calcium phosphate mineralization potentiating the cellular immune response of foot-and-mouth disease virus-like particle vaccines., PMID:40512119

Synergy and antagonism in the integration of BCR and CD40 signals that control B-cell population expansion., PMID:40473841

A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity., PMID:40441493

Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform., PMID:40417977

Adoptively transferred macrophages for cancer immunotherapy., PMID:40413021

Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation., PMID:40387233

Single Treatment Boiling Histotripsy Focused Ultrasound Ablation Neither Negates nor Enhances the Activity of α-CD40 in a Pancreatic Cancer Model., PMID:40372859

Mechanisms of tumor-associated macrophages promoting tumor immune escape., PMID:40371816

Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice., PMID:40360777

Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis., PMID:40358149

Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data., PMID:40347227

Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells., PMID:40341026

The role of soluble CD40L in autoimmune diseases., PMID:40329996

Identification of soluble biomarkers that associate with distinct manifestations of long COVID., PMID:40307449

Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis., PMID:40300121

Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant., PMID:40285479

Multi-epitope microsphere vaccine modified immunological efficacy against LMBV in largemouth bass (Micropterus salmoides)., PMID:40279807

Aerosol Delivery of Hesperetin-Loaded Nanoparticles and Immunotherapy Increases Survival in a Murine Lung Cancer Model., PMID:40278452

Berberine Suppression of Human IgE but Not IgG Production via Inhibition of STAT6 Binding Activity at IgE Promoter by BCL6., PMID:40277916

A promising endeavor against human cytomegalovirus: Predominant epitopes-based recombinant subunit vaccine RHEcIE1/pp65/pp150., PMID:40277436

CD40 promotes AML survival via non-canonical NF-κB signaling and aberrant lipid metabolism., PMID:40252467

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity., PMID:40246582

OMIP-113: Characterization of Cytokine Producing T Cells in Swine., PMID:40231482

The immune checkpoint regulator CD40 potentiates myocardial inflammation., PMID:40217124

Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling., PMID:40217113

Recognition of different subsets of alloreactive T cells by activation-induced markers., PMID:40204006

CAR Treg synergy with anti-CD154 promotes infectious tolerance and dictates allogeneic heart transplant acceptance., PMID:40197364

Modulating IL-21-driven B cell responses in idiopathic inflammatory myopathies via inhibition of the JAK/STAT pathway., PMID:40170058

Integrative miRNA-mRNA profiling uncovers mechanisms of belimumab action in systemic lupus erythematosus., PMID:40160819

Targeted immunotherapies for Graves' thyroidal & orbital diseases., PMID:40145088

Facts and Hopes of CD40 Agonists in Cancer Immunotherapy., PMID:40117130

Lupenone preserves T cell activity by recovery of CD40L expression and protection from cytotoxicity due to methamphetamine exposure., PMID:40111983

Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity., PMID:40111090

Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trial., PMID:40104960

Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement., PMID:40090010

Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors., PMID:40074330

Suppression of NF-κB and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion., PMID:40073262

Comparison of human macrophages derived from peripheral blood and bone marrow., PMID:40073092

Elevated serum CD40 as a potential biomarker for the differential diagnosis of acute thyrotoxic myopathy., PMID:40069315

Influence of environmental exposures on T follicular helper cell function and implications on immunity: a comparison of Bangladeshi and American children., PMID:40062864

IL-1R1 Blockade Boosts CD40 Agonist Immune Responses but Fails to Improve Efficacy or Reduce Hepatotoxicity in Pancreatic Cancer., PMID:40060615

Humanized FcεRI Expressed on Mouse Eosinophils Mediates IgE-Facilitated Eosinophil Antigen Presentation., PMID:39996772

Modified CD40L-Activated B-Cell Proliferation Model for Validating the Suppressive Activity of CD40-CD154 Pathway Inhibitors., PMID:39994946

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer., PMID:39972124

Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer., PMID:39969975

CD40 induces PIR-A+ macrophages to promote chronic allograft rejection., PMID:39954660

Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy., PMID:39941108

Discrimination of Anti-Donor Response in Allogeneic Transplantation Using an Alloreactive T-Cell Detection Assay., PMID:39936124

Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury., PMID:39935575

Deficiency of adenosine deaminase 2 skews adaptive immune repertoires toward specific sets of T- and B-cell receptors., PMID:39924119

Datasheet
$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-CD40/TNFRSF5 Antibody (R3G90) [RHD68904]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only